Roche/Trimeris’ Fuzeon Cited By FDA For Promotions At Scientific Conference
This article was originally published in The Pink Sheet Daily
FDA letter cites claims made by Roche sales rep at last fall’s ICAAC, including that the injectable HIV therapy is “better than oral HIV drugs.” Rep also claimed that the drugs “confers ‘100% antiviral activity,’” FDA says.
You may also be interested in...
Roche/Trimeris' HIV agent Fuzeon (enfuvirtide) has been granted full approval, the companies announced Oct. 15
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.